Ongoing Clinical Trials

ALEXION OCTAGON
Clinical Study

The study aims to evaluate the effectiveness and safety of a re-defined oral corticosteroid (OCS) tapering schedule in adults with generalized Myasthenia Gravis (gMG) receiving ravulizumab (Ultomiris) treatment to see if they can reduce or discontinue OCS without clinical deterioration. 
 
The study is for adult patients with a clinical diagnosis of gMG who currently receive both Ultomiris and OCS therapy as part of routine care.

To qualify, participants generally must:
 

• Must be 18 years of age or older
   

• Have a clinical diagnosis of gMG that is AChR+
   

• Must have been receiving Ultomiris treatment for less than 6 months prior to enrollment

​

• Must have been receiving OCS therapy equivalent to 7.5mg of prednisone/prednisolone for at least 4 or more continuous weeks prior to enrollment